With obesity rates in the United States having tripled since the 1980s, the health care system now faces an annual cost of $173 billion due to obesity-related complications, such as heart disease, hypertension, joint pain and certain types of cancer. And employers, or health plan sponsors, shoulder a substantial portion of these expenses, prompting the question: Could drugs in the latest generation of medications approved to promote weight loss be a solution?
These medications, originally approved to treat type two diabetes mellitus, are known as incretin mimetics or GLP-1s. They work by mimicking a naturally occurring hormone (glucagon like peptide) that affects insulin and glucagon levels and also regulates appetite. One medication in this class is a dual acting agent that in addition to mimicking GLP-1 it mimics another gut hormone, glucose-dependent insulinotropic polypeptide (GIP) which also affects insulin and glucagon levels.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
- Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
- Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
Already have an account? Sign In
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
